Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single Group, Phase 4 Study to Evaluate Dimethyl Fumarate Enteric-coated Capsules in Relapsing Multiple Sclerosis (RMS)

NCT07138833 is registered in ClinicalTrials.gov with Qilu Pharmaceutical (Hainan) Co., Ltd. as lead sponsor.

NCT NCT07138833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07138833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single Group, Phase 4 Study to Evaluate Dimethyl Fumarate Enteric-coated Capsules in Relapsing Multiple Sclerosis (RMS)
Lead sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
August 31, 2028
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis